About US
Contact us
-
AstraZeneca and Daiichi Sankyo field backlash over Super Bowl OIC awareness adA Super Bowl commercial paid for by AstraZeneca ($AZN) andDaiichi Sankyoto stimulate awareness of opioid-induced constipation (OIC) continues to draw controversy, including from the White House, days2016/2/15
-
Sanofi tried and failed with Afrezza. Why does MannKind still think it can win?Can MannKind ($MNKD) really resurrect its inhaled insulinAfrezza? Sanofi ($SNY), a diabetes powerhouse, tried and failed to make a market for the product. Its drawbacks remain. But as theWall Street J2016/2/15
-
Novartis takes aim at Remicade market with EU biosim rights from PfizerSince acquiringHospira, Pfizer's ($PFE) had a pair ofRemicadebiosimilars on its hands. Now, it's making moves to pare that number down to one, and Novartis ($NVS) will be reaping the benefits. The Sw2016/2/14
-
U.K. slaps GSK with $54.4M fine for decade-old pay-for-delay dealThe U.K.'s Competition and Markets Authority was only formed in 2014, but it didn't mind reaching back more than a decade for evidence to slap GlaxoSmithKline ($GSK) with a $54.4 million (£37.62016/2/14
-
GSK and Adaptimmune expand cancer immunotherapy allianceGlaxoSmithKline (GSK) has expanded the collaboration agreement with Adaptimmune to accelerate development of the latter's lead clinical cancer programme, an affinity enhanced T-cell immunotherapy (GSK2016/2/5
-
AstraZeneca acquires 55% stake in Acerta Pharma for $4bnAstraZeneca has completed the acquisition of 55% stake in Acerta Pharma, a privately-owned biopharmaceutical firm, for $4bn. Acerta Pharma has operations in Oss, the Netherlands and several US sites,2016/2/5
-
Can fast-growing Eliquis overtake J&J's Xarelto? Bristol's execs think soEliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has seriously picked up the pace lately, rocketing to the top of Bristol-Myers Squibb's ($BMY) sales charts. And2016/2/4
-
Merck treads water in Q4 as Keytruda helps offset Remicade sufferingMerck & Co. ($MRK) took a one-two punch in the fourth quarter. Revenue from two top-selling franchises--JanuviaandRemicade--slid, dragging overall sales below analyst estimates at $10.2 billion. O2016/2/4
-
EMA validates Gilead’s Type II variation application for Truvada to reduce risk of HIV-1 infectionThe European Medicines Agency (EMA) has validated Gilead Sciences' Type II variation application for once-daily Truvada to reduce the risk of sexually acquired HIV-1 infection among uninfected adults2016/2/3
-
Allergan and AstraZeneca to develop ATM-AVI for antibiotic-resistant gram-negative infectionsIrish drug-maker Allergan has entered into a global agreement with UK's AstraZeneca to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.2016/2/3